Helen Harrison

Title: Helen Harrison: Innovator in Bicyclic Peptide Ligands

Introduction

Helen Harrison, based in Cambridge, GB, is a noteworthy inventor recognized for her contributions to the field of biotechnology. With a focus on polypeptide innovations, she has secured a patent that showcases her expertise and determination to advance therapeutic applications.

Latest Patents

Helen's sole patent, titled "Bicyclic peptide ligands specific for OX40," presents groundbreaking polypeptides that are covalently attached to molecular scaffolds. These innovative peptides feature two or more loops stemming from the attachment points, enabling specific binding to the OX40 receptor. The invention also explores multimeric binding complexes that act as functional agonists of OX40. Furthermore, the patent includes drug conjugates that comprise these peptides and complexes, aimed at preventing, suppressing, or treating diseases or disorders mediated by OX40. This work holds significant potential for therapeutic advancements in targeting OX40 pathways.

Career Highlights

Helen is associated with Bicycletx Limited, where she has played an integral role in the development of her patented innovations. Her dedication to her research and commitment to harnessing the power of bioconjugates underlines her impact in the industry.

Collaborations

In her professional journey, Helen collaborates with colleagues such as Tom Li Stephen and Kevin McDonnell, contributing to a dynamic team focused on innovative solutions in biotechnology. These collaborations not only enhance her research but also foster a creative environment for tackling complex challenges in medicine.

Conclusion

Helen Harrison stands out as a significant figure in the realm of peptide innovations. Her patent on bicyclic peptide ligands marks a crucial step towards developing new therapies for diseases linked to the OX40 receptor. As her career progresses at Bicycletx Limited, her contributions promise to influence future advancements in the field of biotechnology.